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The success of in vivo gene therapy greatly depends on the ability to control the immune
response toward the therapeutic transgene. Over the last decade several vector-based
and pharmacological approaches have been explored to control the immune-mediated
clearance of transgene-expressing cells after viral delivery. One important outcome from
these studies is the concept that expression of a transgene in tolerance-promoting organs,
such as the liver and tolerogenic antigen-presenting cells, can help safeguard transgene-
expressing cells from immune-mediated clearance. Gene therapists are now manipulating
vectors to target naturally occurring tolerogenic properties of the body by: (i) incorporating
tissue/cell speciﬁc promoters for targeted expression, (ii) using viral-capsid engineering
to alter tropism and avoid pre-existing immunity, and (iii) regulating cell and activation
dependent expression by including micro-RNA (miR) targets into expression cassettes.
The combination of these three layers of vector regulation greatly enhances the targeting
of tolerogenic cells and limits off-target expression of the transgene, which can lead to the
induction of transgene-speciﬁc pathogenic effector T cells. In this review, we discuss the
application of using miR transgene regulation to generate tolerogenic responses and spec-
ulate on possible mechanisms used by the liver to induce the transgene-speciﬁc regulatory
T cells.
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INTRODUCTION
A major obstacle for achieving therapeutic efﬁcacy when using
in vivo gene therapy is the development of an immune response
toward the transgene since pathogenic immune responses can
lead to the clearance of transgene-expressing cells. While long-
term transgene expression has been achieved in several clini-
cal trials using direct viral-vector administration (Kaplitt et al.,
2007; Bainbridge et al., 2008; Hauswirth et al., 2008), target-
ing immune-privileged sites like the eye, brain, and testis as was
done in these trials suggests that selective transgene expression
in immune-privileged tissues (for review see Lowenstein et al.,
2007) may diminish but not necessarily abolish the need for vec-
tor modiﬁcation and/or pharmacological help to maintain trans-
gene expression. Unfortunately for many individuals in need of
gene therapy, disease correction requires delivery of a vector to
immune-competent organs and requires robust local or systemic
expression of a therapeutic protein. To combat the potential loss of
transgene expression due to immune complications, gene thera-
pists are modifying gene delivery platforms and using therapeutic
regimens (such as immunosuppressive drugs) to promote toler-
ance toward the transgene. In this review, we focus on the use
of vector modiﬁcation with micro-RNA (miR) targets to regulate
transgene expression and how they can be used with other layers
of vector modiﬁcation to promote transgene tolerance.
IMMUNE TOLERANCE
Tolerance is a naturally occurring process that uses one or more
immunemechanisms to achieve immunological homeostasis. One
means to achieve a tolerogenic state toward an antigen (Ag) is
through passive tolerance, which is a quiescent immunological
state where T cells do not come into contact with their cognate Ag
or where effector T cells (Teff) are deleted or anergized upon Ag
recognition, resulting in immune ignorance. Active tolerance, on
the other hand, is a dynamic process whereby FoxP3-expressing
regulatory T cells (Treg) work to suppress inﬂammatory immune
responses in Ag-speciﬁc and non-speciﬁc ways (Fehervari and
Sakaguchi, 2004a; Sakaguchi et al., 2008). Among the Treg sub-
populations are the naturally occurring Treg (nTreg), which are
differentiated in the thymus, and the induced Treg (iTreg) which
are induced in the periphery, are phenotypically similar and have
similar regulatory properties; however, the relative contribution
of iTreg and nTreg in regulating immune responses in different
disease states is subject to ongoing discussions. Nevertheless, Treg
induction and expansion have become a focal point by some gene
therapists for developing tolerance to therapeutic proteins because
of their potent regulatory properties (Luth et al., 2008;Nayak et al.,
2009).
TOLEROGENIC NATURE OF THE LIVER
Liver architecture creates a unique immunological site where cir-
culating Ags and immune cells can meet. In a healthy state, natural
tolerogenic mechanisms of the liver ensure that immunity against
innocuousAg (gut-derived nutrients and damaged/aged cells) and
potentially immunogenic Ag (gut ﬂora-derived) are kept in check.
The means by which the liver induces this tolerance is partly
attributed to the composition and diversity of antigen-presenting
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cells (APC) and the presence of regulatory cytokines. The liver
accommodates a variety of cells equipped to engage T cells,
including canonical APC like liver-resident macrophages (Kupf-
fer cells, KC) and conventional- and plasmacytoid-dendritic cells
(cDC, pDC respectively), and non-canonical APC like liver sinu-
soidal endothelial cells (LSEC), and stellate cells (SC) and hepa-
tocytes that are able to process and present Ag, secrete regulatory
cytokines, and provide co-stimulatory molecules (Knolle et al.,
1999; Limmer et al., 2000; Warren et al., 2006). Furthermore, all
of these cells, with the exception of hepatocytes [which are deﬁ-
cient in MHC-class (MHC) – II expression] have been implicated
in the generation of Treg and reported as one of the important
biomarkers for predicting successful liver engraftment without
immunosuppression (Seyfert-Margolis and Turka, 2008).
The tolerogenic properties of liver APC can be ascribed to the
consistent expression of anti-inﬂammatory cytokines and other
tolerogenic molecules found in a hepatic micro-environment.
The liver is a rich source of IL-10 and TGF-β, both of which
are potent modulators of APC differentiation, trafﬁcking, and
function (Lau and Thomson, 2003). In the absence of the IL-
10 gene or blocking IL-10 with a recombinant IL-10R fusion
protein, hepatic tolerance is not established in a ConA induced
model of hepatitis, signifying the central role of this cytokine
in maintaining tolerance (Erhardt et al., 2007). In the Erhardt
et al. study, KC were shown to be the key source of IL-10, but
more importantly, the lack of IL-10 expression by Treg was a
critical factor for resolving inﬂammation, suggesting that IL-10
is needed by APC and T cells to maintain tolerance. TGF-β
was originally recognized as a growth factor for non-immune
cells and only later as an inhibitory signal for activation of
immune cells, preventing activation of macrophages and mat-
uration of DC and modulating effector functions of T and B
cells (Chen and Konkel, 2010). Chen and colleagues showed
that TGF-β signaling coupled with TCR stimulation convert
CD4+CD25−Foxp3− into iTreg. Thus, hepatic architecture, posi-
tion, and micro-environment encourage interactions between
non-parenchymal cells and circulating lymphocytes in the pres-
ence of immunoregulatory cytokines.Additionally, 50%of hepatic
Treg are also Ki-67+ (unpublished data by our group) supporting
the hypothesis that the liver could be a preferential site for the
expansion of Treg. Overall, these features distinguish the liver as
a potential site for the development and expansion of acquired
peripheral tolerance.
PROMOTER AND VECTOR MODULATION TO REDUCE
TRANSGENE IMMUNITY
Tissue-speciﬁc promoters that restrict transgene expression to a
targeted cell type have been widely employed in gene therapy
to avoid immune responses. The basic concept for using tissue-
speciﬁc promoters is to drive expression of the therapeutic trans-
gene to target cells while preventing its expression in APC in order
to avoid the priming of Teff (Vandendriessche et al., 2007). Despite
the speciﬁcity of tissue-speciﬁc promoters, their use as a regula-
tory layer does not necessarily prevent immune responses toward
the encoded transgene. We among others have found that the use
of promoters speciﬁc for tolerogenic cells such as hepatocytes
can still lead to transgene-speciﬁc neutralizing antibodies and
immune-mediated clearance of transgene-expressing cells (Brown
et al., 2004; Follenzi et al., 2007; Herzog, 2007; Haribhai et al.,
2011; Mingozzi and High, 2011). These results may be due to
non-speciﬁc activity of the promoter, cross-priming, or in the case
of integrating vectors, promoter-enhancer trapping at insertions
near active regions of transcription (De Palma et al., 2005). Taken
together, tissue-speciﬁc promoters can foster transgene stability
by avoiding immune responses and enhancing tissue targeting in
many cases; however, the use of tissue-speciﬁc promoters does
not guarantee that transgene tolerance will be achieved in all
immunological settings.
Alternating viral-capsid proteins to avoid pre-existing immu-
nity and/or the development of immunity toward the vector and
transgene is another approach by which gene therapists can max-
imize transgene expression. Viral capsids are immunogens, which
can trigger innate and adaptive immune responses and lead to
the development of neutralizing antibodies toward the vector as
well as capsid-speciﬁc-Teff responses. In fact, it is believed that the
ﬁrst clinical trial for hemophilia B using adeno-associated vector
(AAV) to deliver the factor IX (FIX) transgene failed due to pre-
existing anti-AAV immune responses that led to the clearance of
the transduced cells (Prasad et al., 2001; Li et al., 2007; Mingozzi
et al., 2007). The use of pseudocapsids or particular serotypes
with viral gene therapy can avoid existing antibody or cellular
immune responses to the vector if the Ags of the introduced cap-
sid protein(s) are naïve/less immunogenic to the immune system.
In addition, swapping or novel capsid proteins can alter tropism
of the vector and de-target APC. Kang et al. (2005) showed that
in the case of long-term factor VIII (FVIII) expression the use
of a gp64 capsid protein in lieu of the canonical VSV-G capsid
protein in a feline immunodeﬁciency vector was able to partially
correct disease in hemophilia A mice. However, when a gp64 lenti-
viral (LV) vector was used in the same mouse model, Lillicrap
and colleagues were unable to achieve long-term FVIII expres-
sion unless the expression was combined with another layer of
gene regulation (Matsui et al., 2011). While these results suggest
that tissue-speciﬁc promoters and viral pseudotyping can improve
transgene expression and long-term outcome of gene therapy
with viral vectors, they also suggest that more regulation may be
required to achieve transgene-speciﬁc tolerance in more stringent
immunological settings.
miR TRANSGENE REGULATION
Molecular engineering of viral-vector cassettes with miR targets
is the latest attempt at regulating expression in gene therapy. miR
are a family of endogenously expressed, small, non-coding RNA
of∼22 nucleotides that are post-transcriptional regulators of gene
expression and inhibit expression by binding to miR targets on
mRNA to repress transcription or to promote mRNA degradation.
Similar to the way miR regulates the expression of genes natu-
rally encoding miR targets, vectors engineered with miR targets
can prevent transgene expression in the transduced cells provided
the target cells express the particular miR matching the miR tar-
get encoded in the vector (Brown and Naldini, 2009). Since miR
are intimately involved in a variety of immunological processes,
including B and T cell development, hematopoietic cell differen-
tiation, apoptosis, and proliferation (Landgraf et al., 2007; Kelly
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and Russell, 2009), the incorporation of miR target sequences in
vectors makes it possible to direct expression to or away from
particular cells of the immune system by exploiting their natural
miR proﬁle. miR expression proﬁles vary considerably from being
constitutively expressed or induced to shut off, depending on cell
type and maturation state (Petriv et al., 2010). This variability sug-
gests that by incorporating miR targets in vectors, it is possible to
target transgene expression not only to certain cell types, but also
to certain stages of cell differentiation or activation. The ability
to regulate gene expression at a state-speciﬁc level is of particular
interest to gene therapists because it adds a new dimension of reg-
ulating gene expression that cannot be achieved by other vector
modiﬁcations.
miR TO GENERATE IMMUNE TOLERANCE
One attractive approach to generate immune tolerance is to direct
transgene expression towardAPC in a tolerogenic state. The imma-
ture state of someAPC is considered to have tolerogenic properties
because they lack the necessary molecules needed to induce robust
immune responses. Our group among others has shown that
immature dendritic cells (iDC) are a potent inducer of Treg and,
therefore, have become targets for inducing Treg (Wakkach et al.,
2003; Levings et al., 2005; Yamazaki and Steinman, 2009). The
mechanisms by which iDC promote Treg induction is through the
expression of tolerance-promoting cytokines, such as IL-10 (Gre-
gori et al., 2010) and TGF-β (Wakkach et al., 2003; Fehervari and
Sakaguchi, 2004b) and the surface expression of tolerogenic co-
stimulatorymolecules such as PDL-1 (Unger et al., 2009); however,
a major caveat for targeting iDC is the short window of opportu-
nity for maximizing their tolerogenic abilities since activated DC
produce inﬂammatory cytokines and up-regulate co-stimulatory
molecules that promote the development of Teff. Therefore, in the
scenario of exploiting the tolerogenic state of APC it is vital to
limit Ag expression to the tolerogenic state of the cell and turning
off expression once the APC is activated. Using miR targets in the
vector can take advantage of the unique state-speciﬁc miR expres-
sion of APC to accomplish this goal. iDC, for example, do not
express miR-122, -146a, or -155 in the immature state, however,
upon activation by cytokines or TLR ligands thesemiR are induced
and become highly expressed by the DC (Taganov et al., 2006;
Jurkin et al., 2010). Therefore, using a vector regulated by miR
targets encoding for miR-122, -146a, or -155 targets could elim-
inate transgene expression of transgene in DC upon activation.
Brown et al. (2007b) showed that state-speciﬁc regulation is pos-
sible with a LV.GFP miR-155 target encoded construct, where GFP
is selectively expressed in the immature state of human periph-
eral blood-derived DC, while GFP expression was dramatically
reduced upon LPS activation of the DC. While this approach has
been proven feasible for selective targeting of iDC, more work
needs to be done to determine the immunological consequence of
this approach and whether it can be used in vivo.
An established strategy for generating transgene tolerance with
miR-containing vectors is to de-target transgene expression of the
hematopoietic system while expressing the transgene in hepato-
cytes.All cells of the hematopoietic systemhighly expressmiR-142;
therefore, vectors including miR-142 targets can repress transgene
expression in all cells of this linage including APC. The effective-
ness of using miR-142-targeted vectors to eliminate expression
in APC and generate transgene tolerance was ﬁrst achieved by
Naldini and colleagues who showed that including miR-142 tar-
get repeats in a LV.GFP vector reduced GFP expression in mouse
macrophages and DC to undetectable levels while maintaining
GFP expression in non-hematopoietic tissues (Brown et al., 2006).
The same group went on to show that hemophilia B can be
cured when FIX deﬁcient mice receive a LV expressing human
FIX under the regulation of miR-142 targets, whereas the ani-
mals receiving the same LV without miR-142 targets cleared the
transgene-expressing cells (Brown et al., 2007a). Interestingly,
the original belief that miR-142-targeted vectors promote trans-
gene tolerance through immune ignorance due to de-targeting of
APC recently changed when we showed induction of Treg using
a LV. GFP, miR-142-targeted vectors with liver-speciﬁc promot-
ers mediate transgene tolerance (Annoni et al., 2009). To prove
that active tolerance is at play in regulating transgene expres-
sion with miR-142 vectors, we showed that in a collaborative
effort that mice injected with LV encoding the Ag ovalbumin
(OVA), liver-speciﬁc promoter, and miR-142-targeted sequences
along with naïve, OVA-speciﬁc T cells induces OVA-speciﬁc Treg,
suggesting that Ag-speciﬁc iTreg are regulating transgene toler-
ance (Matrai et al., 2011). The concept that Ag-speciﬁc Treg are
regulating tolerance is supported by the fact that upon pDNA re-
challenge with the transgene, tolerized mice showed little response
to the Ag, while mice that cleared the transgene-expressing cells
showed increased reactivity (Annoni et al., 2009; Matrai et al.,
2011).
An important point to consider in most of the experimental
conditions used to generate transgene tolerance with miR targets
is the preferential targeting of the transgene to the hepatocytes.
It is important to note, however, that targeting expression to
hepatocytes and de-tartgeting APC do not guarantee transgene
persistence. Osborn et al. (2011) showed in a mucopolysacchari-
dosis type I mouse model that hydrodynamic injection of mini-
circle DNA expressing α-L-iduronidase (IDUA) regulated by liver-
speciﬁc promoter and miR-142 targets mice do not tolerate IDUA
and must receive immunosuppression in order to achieve long-
term transgene expression. In this study it was unclear why IDUA
expression was lost; however, it was speculated that immuno-
genicity of the transgene and/or the acute inﬂammation from
the hydrodynamic injection lead to the clearance of the trans-
gene. This result stresses the importance of selecting a vector
delivery platform/method that has the least amount of immuno-
genicity and selecting or modifying the transgene in order to
reduce the immune response. Despite the failure of this proto-
col, targeting hepatocytes still remains one of the best options
for gene delivery because of their ability to secrete high levels
of protein and the innate tolerogenic properties; however, the
exact mechanism(s) the liver uses to induce tolerance still remains
a mystery. To better understand how hepatocyte-targeted gene
therapy with miR regulated vectors generates transgene-speciﬁc
Treg after gene therapy we are addressing the tolerogenic proper-
ties particular to the liver-resident cells that promote tolerogenic
responses.
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HOW TARGETING AG EXPRESSION TO HEPATOCYTES BY
MIR-REGULATED VECTOR GENERATES TOLERANCE: A
POSSIBLE MECHANISM
Based on our data, we have developed a hypothesis explaining
the mechanisms leading to tolerance using liver-directed, miR-
142 regulated LV gene therapy. So far, we have learned that LV
containing miR-142 targets (LV.142T) and conventional LV have
similar transduction efﬁciency and immunogenicity toward vec-
tor components. In fact, the immune response to LV.142T vector
RNA compared to conventional LV vectors in infected pDC results
in comparable levels of type 1 IFN release after TLR7 triggering
(Brownet al.,2007c).However, sinceLV.142T suppresses transgene
expression in APC, the encoded Ag avoids presentation by IFN α-
β-activated professional APC, thus circumventing the induction
of a robust transgene-speciﬁc CD8+ Teff cell responses. Nev-
ertheless, CD8+ T cell priming occurs among LV.142T infected
hepatocytes due to their expression of MHC-I molecule and co-
stimulatory molecules; however, Teff priming by hepatocytes is
short-lived due to the low levels of MHC-I expression and lack of
key co-stimulatory molecules needed to sustain Teff activation
and expansion. Therefore, in this scenario miR-142 regulation
indirectly causes alterations to T cell signal 1 (MHC-pep) and
signal 2 (co-stimulation) that are necessary for optimal T cell
priming. In addition, very little is known about signal 3 (cytokine
milieu) at the time of Ag-presentation in this model, but given
the reduced priming and Teff memory formation using LV.142T,
it is likely that altered levels of IL-7, IL-15, and TGF-β in the
liver micro-environment play a role in reducing the Teff response
(Sawa et al., 2009). Thus, despite de-targeting APC with LV.142T,
transgene-speciﬁc CD8+ Teff do occur, but since they are subopti-
mally primed by the hepatocytes, there is a premature contraction
phase and reduced cytotoxic effects.
It is difﬁcult to interpret how the generation of Treg occurs
using LV.142T vectors since the primary expressing cell (hepato-
cytes) inefﬁciently express MHC-II necessary for priming CD4+
T cells, and the transgene is not expressed in the professional APC.
Our hypothesis is that CD4+ T cells are primed by APC that have
engulfed the Ag expelled from transduced dead or dying hepa-
tocytes and/or by engulﬁng the dead cells and cross-presenting
the Ag. After engulfment and presentation by APC, the Ag can
prime naïve CD4+ T cells under a tolerogenic cytokine milieu
(signal 3) that promotes the induction of transgene-speciﬁc Treg
cells. Since the liver micro-environment is rich in TGF-β which
is required to convert naïve CD4+ T cells into iTreg (Chen et al.,
2003), it is likely the low level of Ag-presentation by APC com-
bined with the presence of TGF-β provided by the hepatocytes
that evokes iTreg generation. In addition, we have demonstrated
that active tolerance to transgene expressed via integrase defective
(ID) IDLV.142Tplatformoutlasts thewindowof transgene expres-
sion (Matrai et al., 2011), suggesting that tolerance induction and
Tregs conversion are related to tolerogenic Ag-presentation rather
than Ag-persistence.
CONCLUSION
In summary, transgene immunity can be overcome when using
in vivo gene therapy by exploiting vectors that have been designed
to take advantage of the tolerogenic properties of the body.
The recent incorporation of molecular de-targeting techniques
achieved with miR targets combined with tissue-speciﬁc promot-
ers and capsid engineering provides a potent regulatory scheme
that, when designed correctly, can induce Treg capable of con-
trolling transgene-speciﬁc-Teff and prolong transgene expres-
sion. While miR targeting of viral vectors has not been tested
in humans, the transition of miR targets into clinical vectors
is very appealing since most clinical trials will be challenged
by the problem of maintaining immune tolerance. However,
before miR targeted vectors can be widely accepted, they must
be tested in large-animal models for efﬁcacy, safety and conﬁr-
mation that the approach of targeting the liver to induce tol-
erance is similar in rodents and non-human primates. In due
time, it is likely that miR regulation will become commonplace
in the clinical arena given its efﬁciency, potential tolerogenic
properties, and the broad spectrum of miR that are naturally
expressed.
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